Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Segment Reporting

In the periods set out below, revenues by major product were as follows:

	Three months ended June 30,				Six months ended June 30,
(In millions)	2017		2016		2017		2016
Product sales:
HEMOPHILIA	$	743.9	$	275.6	$	1,394.3	$	275.6
INHIBITOR THERAPIES	220.7		74.0		441.2		74.0
Hematology total	964.6		349.6		1,835.5		349.6
CINRYZE	175.9		173.0		401.8		337.2
ELAPRASE	161.0		154.0		301.6		277.6
FIRAZYR	137.4		136.7		265.9		265.0
REPLAGAL	122.1		118.4		231.8		221.6
VPRIV	87.9		88.0		167.7		171.6
KALBITOR	20.6		17.7		32.3		28.1
Genetic Diseases total	704.9		687.8		1,401.1		1,301.1
IMMUNOGLOBULIN THERAPIES	510.5		138.2		1,008.8		138.2
BIO THERAPEUTICS	172.2		51.3		350.1		51.3
Immunology total	682.7		189.5		1,358.9		189.5
VYVANSE	518.2		517.7		1,081.9		1,026.9
ADDERALL XR	71.4		101.8		136.3		200.6
MYDAYIS	15.7		—		15.7		—
Other Neuroscience	30.1		35.7		54.8		57.8
Neuroscience total	635.4		655.2		1,288.7		1,285.3
LIALDA/MEZAVANT	207.8		193.7		382.9		361.7
PENTASA	83.3		72.9		152.4		136.9
GATTEX/REVESTIVE	75.3		44.5		144.3		96.2
NATPARA	34.5		19.9		64.2		35.5
Other Internal Medicine	83.4		88.7		159.3		173.3
Internal Medicine total	484.3		419.7		903.1		803.6
Oncology total	62.5		20.3		120.8		20.3
Ophthalmology total	57.4		—		96.0		—
Total Product sales	3,591.8		2,322.1		7,004.1		3,949.4
Royalties and other revenues:
SENSIPAR royalties	46.4		35.6		85.3		73.5
ADDERALL XR royalties	13.4		5.2		25.9		11.0
FOSRENOL royalties	12.1		11.4		20.7		20.6
3TC and ZEFFIX royalties	8.2		12.1		22.7		27.1
Other royalties and revenues	73.9		42.7		159.4		56.8
Total Royalties and other revenues	154.0		107.0		314.0		189.0
Total Revenues	$	3,745.8	$	2,429.1	$	7,318.1	$	4,138.4